Radotinib‐induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor. (19th July 2015)

• Record Type: Journal Article
• Authors: Won, K. H.; Jo, S. Y.; Lee, Y. J.; Chang, S. E.
• Is Part Of: Clinical and experimental dermatology. Volume 41:Number 2(2016)
• Page Start: 162
• Page End: 165
• Publication Date: 2015-07-19
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.12706
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: Tyrosine kinase inhibitors (TKIs) are associated with various adverse cutaneous reactions, including pigmentary changes. Radotinib is a novel and selective BCR‐ABL1 TKI, which has shown activity and safety in the treatment of patients with chronic myeloid leukaemia resistant or intolerant to imatinib. A 69‐year‐old Korean man presented with lentiginosis after taking radotinib for 6 months. On histopathological examination, the numbers of melanocytes and melanin pigment were found to be increased due to c‐KIT activation, consequently upregulating microphthalmia‐associated transcription factor. This finding is in contrast to previous reports analysing the mechanisms of previously reported tyrosine kinase inhibitors inhibiting c‐KIT.